{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:51:21Z","timestamp":1785876681256,"version":"3.56.0"},"reference-count":120,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>The aim of this study was to compare the efficacy and safety of treatment with Janus kinase inhibitors for alopecia areata, measured by change in Severity of Alopecia Tool (SALT) score. A systematic review following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was performed using Medline, EMBASE and Cochrane library. All studies investigating the efficacy of treatments for alopecia areata were included. Primary outcomes were the proportion of patients with alopecia areata achieving 30%, 50%, 75%, 90% and 100% improvement in SALT score after treatment with a Janus kinase inhibitor. A meta-analysis was performed including all randomized controlled trials investigating Janus kinase inhibitors. A total of 37 studies matched the inclusion criteria and were included. Meta-analysis was performed based on 5 randomized studies. Regarding patients with alopecia areata defined as \u2265\u200950% scalp hair loss, baricitinib 4 mg once daily demonstrated the highest efficacy. However, among patients with alopecia areata defined as a SALT score \u2265\u200950, oral deuruxolitinib 12 mg twice daily demonstrated the highest efficacy. Deuruxolitinib and baricitinib appear to be promising drugs for the treatment of alopecia areata. However, the response depends on the dosage of the drug. More randomized trials, with identical inclusion criteria and dose and duration of treatment, are required to confirm these findings.<\/jats:p>","DOI":"10.2340\/actadv.v103.4536","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T15:08:38Z","timestamp":1674659318000},"page":"adv00855","source":"Crossref","is-referenced-by-count":25,"title":["Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis"],"prefix":"10.2340","volume":"103","author":[{"given":"Farnam","family":"Barati Sedeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorunn El\u00edsabet","family":"Michaelsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias Arvid Simon","family":"Henning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor Borut Ernst","family":"Jemec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina Sophie","family":"Ibler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"25225","doi-asserted-by":"crossref","unstructured":"Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol 2019; 10: 2847.","DOI":"10.3389\/fimmu.2019.02847"},{"key":"25226","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fimmu.2019.02847","DOI":"10.3389\/fimmu.2019.02847"},{"key":"25227","doi-asserted-by":"crossref","unstructured":"Uzuncakmak TK, Engin B, Serdaroglu S, Tuzun Y. Demographic and clinical features of 1,641 patients with alopecia areata, alopecia totalis, and alopecia universalis: a single-center retrospective study. Skin Appendage Disord 2021; 7: 8-12.","DOI":"10.1159\/000510880"},{"key":"25228","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000510880","DOI":"10.1159\/000510880"},{"key":"25229","doi-asserted-by":"crossref","unstructured":"Yang S, Yang J, Liu JB, Wang HY, Yang Q, Gao M, et al. The genetic epidemiology of alopecia areata in China. Br J Dermatol 2004; 151: 16-23.","DOI":"10.1111\/j.1365-2133.2004.05915.x"},{"key":"25230","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2004.05915.x","DOI":"10.1111\/j.1365-2133.2004.05915.x"},{"key":"25231","doi-asserted-by":"crossref","unstructured":"Guzm\u00e1n-S\u00e1nchez DA, Villanueva-Quintero GD, Alfaro Alfaro N, McMichael A. A clinical study of alopecia areata in Mexico. Int J Dermatol 2007; 46: 1308-1310.","DOI":"10.1111\/j.1365-4632.2007.03320.x"},{"key":"25232","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-4632.2007.03320.x","DOI":"10.1111\/j.1365-4632.2007.03320.x"},{"key":"25233","doi-asserted-by":"crossref","unstructured":"Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. J Invest Dermatol 2014; 134: 1141-1142.","DOI":"10.1038\/jid.2013.464"},{"key":"25234","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/jid.2013.464","DOI":"10.1038\/jid.2013.464"},{"key":"25235","doi-asserted-by":"crossref","unstructured":"Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol 2015; 24: 397-403.","DOI":"10.2147\/CCID.S53985"},{"key":"25236","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CCID.S53985","DOI":"10.2147\/CCID.S53985"},{"key":"25237","doi-asserted-by":"crossref","unstructured":"Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med 2012; 366: 1515-1525.","DOI":"10.1056\/NEJMra1103442"},{"key":"25238","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMra1103442","DOI":"10.1056\/NEJMra1103442"},{"key":"25239","unstructured":"Johnson R, Roh E, Saavedra A, Wolff K. Fitzpatrick's colour atlas and synopsis of clinical dermatology. 8th edn. New York: McGrawHill Edu; 2017."},{"key":"25240","doi-asserted-by":"crossref","unstructured":"Rodriguez TA, Fernandes KE, Dresser KL, Duvic M. National Alopecia Areata Registry. Concordance rate of alopecia areata in identical twins supports both genetic and environmental factors. J Am Acad Dermatol 2010; 62: 525-527.","DOI":"10.1016\/j.jaad.2009.02.006"},{"key":"25241","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2009.02.006","DOI":"10.1016\/j.jaad.2009.02.006"},{"key":"25242","doi-asserted-by":"crossref","unstructured":"Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part II. Treatment. J Am Acad Dermatol 2010; 62: 191-202.","DOI":"10.1016\/j.jaad.2009.10.031"},{"key":"25243","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2009.10.031","DOI":"10.1016\/j.jaad.2009.10.031"},{"key":"25244","doi-asserted-by":"crossref","unstructured":"Tr\u00fceb RM, Dutra H, Dias MFRG. A comment on JAK inhibitors for treatment of alopecia areata. Int J Trichology 2018; 10: 193-197.","DOI":"10.4103\/ijt.ijt_62_18"},{"key":"25245","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4103\/ijt.ijt_62_18","DOI":"10.4103\/ijt.ijt_62_18"},{"key":"25246","doi-asserted-by":"crossref","unstructured":"Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol 2018; 78: 15-24.","DOI":"10.1016\/j.jaad.2017.04.1142"},{"key":"25247","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2017.04.1142","DOI":"10.1016\/j.jaad.2017.04.1142"},{"key":"25248","doi-asserted-by":"crossref","unstructured":"Zheng C, Tosti A. Alopecia areata: new treatment options including Janus kinase inhibitors. Dermatol Clin 2021; 39: 407-415.","DOI":"10.1016\/j.det.2021.03.005"},{"key":"25249","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.det.2021.03.005","DOI":"10.1016\/j.det.2021.03.005"},{"key":"25250","doi-asserted-by":"crossref","unstructured":"Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014; 20: 1043-1049.","DOI":"10.1038\/nm.3645"},{"key":"25251","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nm.3645","DOI":"10.1038\/nm.3645"},{"key":"25252","doi-asserted-by":"crossref","unstructured":"Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv 2015; 1: e1500973.","DOI":"10.1126\/sciadv.1500973"},{"key":"25253","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1126\/sciadv.1500973","DOI":"10.1126\/sciadv.1500973"},{"key":"25254","doi-asserted-by":"crossref","unstructured":"Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther 2018; 27: 2323-2335.","DOI":"10.2147\/DDDT.S172638"},{"key":"25255","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/DDDT.S172638","DOI":"10.2147\/DDDT.S172638"},{"key":"25256","doi-asserted-by":"crossref","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151: W65-W94.","DOI":"10.7326\/0003-4819-151-4-200908180-00136"},{"key":"25257","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00136","DOI":"10.7326\/0003-4819-151-4-200908180-00136"},{"key":"25258","doi-asserted-by":"crossref","unstructured":"Benton S, Farah R, Freese R, Hordinsky M. Tofacitinib as a pragmatic treatment choice for alopecia areata: a retrospective review. Dermatol Ther 2022; 35: e15310.","DOI":"10.1111\/dth.15310"},{"key":"25259","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.15310","DOI":"10.1111\/dth.15310"},{"key":"25260","doi-asserted-by":"crossref","unstructured":"King B, Mesinkovska N, Mirmirani P, Bruce S, Kempers S, Guttman-Yassky E, et al. Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata. J Am Acad Dermatol 2022; 87: 306-313.","DOI":"10.1016\/j.jaad.2022.03.045"},{"key":"25261","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2022.03.045","DOI":"10.1016\/j.jaad.2022.03.045"},{"key":"25262","doi-asserted-by":"crossref","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 2022; 386: 1687-1699.","DOI":"10.1056\/NEJMoa2110343"},{"key":"25263","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2110343","DOI":"10.1056\/NEJMoa2110343"},{"key":"25264","doi-asserted-by":"crossref","unstructured":"Mikhaylov D, Glickman JW, Del Duca E, Nia J, Hashim P, Singer GK, et al. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res 2022; Mar 1. [Online ahead of print]","DOI":"10.1007\/s00403-022-02336-0"},{"key":"25265","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00403-022-02336-0","DOI":"10.1007\/s00403-022-02336-0"},{"key":"25266","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Del Duca E, Estrada Y, et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol 2022; 149: 1318-1328.","DOI":"10.1016\/j.jaci.2021.10.036"},{"key":"25267","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2021.10.036","DOI":"10.1016\/j.jaci.2021.10.036"},{"key":"25268","doi-asserted-by":"crossref","unstructured":"Esteves M, Lopes S, Azevedo F, Pedrosa A. Effectiveness of oral tofacitinib dose tapering in a case of alopecia areata universalis. Skin Appendage Disord 2021; 7: 36-40.","DOI":"10.1159\/000510673"},{"key":"25269","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000510673","DOI":"10.1159\/000510673"},{"key":"25270","doi-asserted-by":"crossref","unstructured":"Jerjen R, Meah N, Trindade de Carvalho L, Wall D, Eisman S, Sinclair R, et al. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: A retrospective study. Pediatr Dermatol 2021; 38: 103-108.","DOI":"10.1111\/pde.14422"},{"key":"25271","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/pde.14422","DOI":"10.1111\/pde.14422"},{"key":"25272","doi-asserted-by":"crossref","unstructured":"Lai VWY, Bokhari L, Sinclair R. Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. Int J Dermatol 2021; 60: 1135-1139.","DOI":"10.1111\/ijd.15657"},{"key":"25273","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ijd.15657","DOI":"10.1111\/ijd.15657"},{"key":"25274","doi-asserted-by":"crossref","unstructured":"King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol 2021; 85: 379-387.","DOI":"10.1016\/j.jaad.2021.03.050"},{"key":"25275","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2021.03.050","DOI":"10.1016\/j.jaad.2021.03.050"},{"key":"25276","doi-asserted-by":"crossref","unstructured":"King B, Ko J, Forman S, Ohyama M, Mesinkovska N, Yu G, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study. J Am Acad Dermatol 2021; 85: 847-853.","DOI":"10.1016\/j.jaad.2021.05.050"},{"key":"25277","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2021.05.050","DOI":"10.1016\/j.jaad.2021.05.050"},{"key":"25278","doi-asserted-by":"crossref","unstructured":"Dincer Rota D, Emeksiz MAC, Erdogan FG, Yildirim D. Experience with oral tofacitinib in severe alopecia areata with different clinical responses. J Cosmet Dermatol 2021; 20: 3026-3033.","DOI":"10.1111\/jocd.13966"},{"key":"25279","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jocd.13966","DOI":"10.1111\/jocd.13966"},{"key":"25280","doi-asserted-by":"crossref","unstructured":"Wambier CG, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. J Am Acad Dermatol 2021; 85: 743-745.","DOI":"10.1016\/j.jaad.2019.08.080"},{"key":"25281","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2019.08.080","DOI":"10.1016\/j.jaad.2019.08.080"},{"key":"25282","doi-asserted-by":"crossref","unstructured":"Kerkemeyer KLS, John JM, Sinclair R, Bhoyrul B. Response of alopecia areata of the beard to oral tofacitinib. J Am Acad Dermatol 2020; 82: 1228-1230.","DOI":"10.1016\/j.jaad.2019.10.058"},{"key":"25283","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2019.10.058","DOI":"10.1016\/j.jaad.2019.10.058"},{"key":"25284","doi-asserted-by":"crossref","unstructured":"Yale K, Pourang A, Plikus MV, Mesinkovska NA. At the crossroads of 2 alopecias: androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors. JAAD Case Rep 2020; 6: 444-446.","DOI":"10.1016\/j.jdcr.2020.02.026"},{"key":"25285","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jdcr.2020.02.026","DOI":"10.1016\/j.jdcr.2020.02.026"},{"key":"25286","doi-asserted-by":"crossref","unstructured":"Akdogan N, Ersoy-Evans S, Do\u011fan S, Atakan N. Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata. Dermatol Ther 2019; 32: e13118.","DOI":"10.1111\/dth.13118"},{"key":"25287","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.13118","DOI":"10.1111\/dth.13118"},{"key":"25288","doi-asserted-by":"crossref","unstructured":"Almutairi N, Nour TM, Hussain NH. Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study. Dermatology 2019; 235: 130-136.","DOI":"10.1159\/000494613"},{"key":"25289","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000494613","DOI":"10.1159\/000494613"},{"key":"25290","doi-asserted-by":"crossref","unstructured":"Chen YY, Lin SY, Chen YC, Yang CC, Lan CE. Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen. Eur J Dermatol 2019; 29: 667-669.","DOI":"10.1684\/ejd.2019.3668"},{"key":"25291","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1684\/ejd.2019.3668","DOI":"10.1684\/ejd.2019.3668"},{"key":"25292","doi-asserted-by":"crossref","unstructured":"Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. J Am Acad Dermatol 2019; 80: 568-570.","DOI":"10.1016\/j.jaad.2018.08.041"},{"key":"25293","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.08.041","DOI":"10.1016\/j.jaad.2018.08.041"},{"key":"25294","doi-asserted-by":"crossref","unstructured":"Dai YX, Chen CC. Tofacitinib therapy for children with severe alopecia areata. J Am Acad Dermatol 2019; 80: 1164-1166.","DOI":"10.1016\/j.jaad.2018.12.041"},{"key":"25295","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.12.041","DOI":"10.1016\/j.jaad.2018.12.041"},{"key":"25296","doi-asserted-by":"crossref","unstructured":"Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol 2019; 80: 566-568.","DOI":"10.1016\/j.jaad.2018.08.040"},{"key":"25297","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.08.040","DOI":"10.1016\/j.jaad.2018.08.040"},{"key":"25298","doi-asserted-by":"crossref","unstructured":"Serdaro\u011flu S, Engin B, \u00c7elik U, Erkan E, A\u015fk\u0131n \u00d6, Oba \u00c7, et al. Clinical experiences on alopecia areata treatment with tofacitinib: a study of 63 patients. Dermatol Ther 2019; 32: e12844.","DOI":"10.1111\/dth.12844"},{"key":"25299","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.12844","DOI":"10.1111\/dth.12844"},{"key":"25300","doi-asserted-by":"crossref","unstructured":"Shin JW, Huh CH, Kim MW, Lee JS, Kwon O, Cho S, et al. Comparison of the treatment outcome of oral tofacitinib with other conventional therapies in refractory alopecia totalis and universalis: a retrospective study. Acta Derm Venereol 2019; 99: 41-46.","DOI":"10.2340\/00015555-3057"},{"key":"25301","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3057","DOI":"10.2340\/00015555-3057"},{"key":"25302","doi-asserted-by":"crossref","unstructured":"Shivanna CB, Shenoy C, Priya RA. Tofacitinib (selective janus kinase inhibitor 1 and 3): a promising therapy for the treatment of alopecia areata: a case report of six patients. Int J Trichology 2018; 10: 103-107.","DOI":"10.4103\/ijt.ijt_21_18"},{"key":"25303","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4103\/ijt.ijt_21_18","DOI":"10.4103\/ijt.ijt_21_18"},{"key":"25304","unstructured":"Cheng MW, Kehl A, Worswick S, Goh C. Successful treatment of severe alopecia areata with oral or topical tofacitinib. J Drugs Dermatol 2018; 17: 800-803."},{"key":"25305","doi-asserted-by":"crossref","unstructured":"Jabbari A, Sansaricq F, Cerise J, Chen JC, Bitterman A, Ulerio G, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Invest Dermatol 2018; 138: 1539-1545.","DOI":"10.1016\/j.jid.2018.01.032"},{"key":"25306","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2018.01.032","DOI":"10.1016\/j.jid.2018.01.032"},{"key":"25307","doi-asserted-by":"crossref","unstructured":"Lee JS, Huh CH, Kwon O, Yoon HS, Cho S, Park HS. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib. J Dermatolog Treat 2018; 29: 819-822.","DOI":"10.1080\/09546634.2018.1466024"},{"key":"25308","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2018.1466024","DOI":"10.1080\/09546634.2018.1466024"},{"key":"25309","doi-asserted-by":"crossref","unstructured":"Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol 2018; 78: 403-404.","DOI":"10.1016\/j.jaad.2017.10.043"},{"key":"25310","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2017.10.043","DOI":"10.1016\/j.jaad.2017.10.043"},{"key":"25311","doi-asserted-by":"crossref","unstructured":"Patel NU, Oussedik E, Grammenos A, Pichardo-Geisinger R. A Case report highlighting the effective treatment of alopecia universalis with tofacitinib in an adolescent and adult patient. J Cutan Med Surg 2018; 22: 439-442.","DOI":"10.1177\/1203475418760512"},{"key":"25312","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1203475418760512","DOI":"10.1177\/1203475418760512"},{"key":"25313","doi-asserted-by":"crossref","unstructured":"Putterman E, Castelo-Soccio L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. J Am Acad Dermatol 2018; 78: 1207-1209.","DOI":"10.1016\/j.jaad.2018.02.031"},{"key":"25314","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.02.031","DOI":"10.1016\/j.jaad.2018.02.031"},{"key":"25315","doi-asserted-by":"crossref","unstructured":"Castelo-Soccio L. Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis. J Am Acad Dermatol 2017; 76: 754-755.","DOI":"10.1016\/j.jaad.2016.11.038"},{"key":"25316","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2016.11.038","DOI":"10.1016\/j.jaad.2016.11.038"},{"key":"25317","doi-asserted-by":"crossref","unstructured":"Deeb M, Beach RA. A case of topical ruxolitinib treatment failure in alopecia areata. J Cutan Med Surg 2017; 21: 562-563.","DOI":"10.1177\/1203475417716363"},{"key":"25318","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1203475417716363","DOI":"10.1177\/1203475417716363"},{"key":"25319","doi-asserted-by":"crossref","unstructured":"Erduran F, Ad\u0131\u015fen E, Aksakal AB. Excellent response to tofacitinib treatment in a patient with alopecia universalis. Acta Dermatovenerol Alp Pannonica Adriat 2017; 26: 47-49.","DOI":"10.15570\/actaapa.2017.15"},{"key":"25320","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.15570\/actaapa.2017.15","DOI":"10.15570\/actaapa.2017.15"},{"key":"25321","doi-asserted-by":"crossref","unstructured":"Ibrahim O, Bayart CB, Hogan S, Piliang M, Bergfeld WF. Treatment of alopecia areata with tofacitinib. JAMA Dermatol 2017; 153: 600-602.","DOI":"10.1001\/jamadermatol.2017.0001"},{"key":"25322","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2017.0001","DOI":"10.1001\/jamadermatol.2017.0001"},{"key":"25323","doi-asserted-by":"crossref","unstructured":"Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 2017; 76: 22-28.","DOI":"10.1016\/j.jaad.2016.09.007"},{"key":"25324","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2016.09.007","DOI":"10.1016\/j.jaad.2016.09.007"},{"key":"25325","doi-asserted-by":"crossref","unstructured":"Park HS, Kim MW, Lee JS, Yoon HS, Huh CH, Kwon O, et al. Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series. J Am Acad Dermatol 2017; 77: 978-980.","DOI":"10.1016\/j.jaad.2017.06.027"},{"key":"25326","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2017.06.027","DOI":"10.1016\/j.jaad.2017.06.027"},{"key":"25327","doi-asserted-by":"crossref","unstructured":"Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata JCI Insight 2016; 1: e89776.","DOI":"10.1172\/jci.insight.89776"},{"key":"25328","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1172\/jci.insight.89776","DOI":"10.1172\/jci.insight.89776"},{"key":"25329","doi-asserted-by":"crossref","unstructured":"Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight 2016; 1: e89790.","DOI":"10.1172\/jci.insight.89790"},{"key":"25330","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1172\/jci.insight.89790","DOI":"10.1172\/jci.insight.89790"},{"key":"25331","doi-asserted-by":"crossref","unstructured":"Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2019; 33: 850-856.","DOI":"10.1111\/jdv.15489"},{"key":"25332","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15489","DOI":"10.1111\/jdv.15489"},{"key":"25333","doi-asserted-by":"crossref","unstructured":"Guo L, Feng S, Sun B, Jiang X, Liu Y. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol 2020; 34: 192-201.","DOI":"10.1111\/jdv.15937"},{"key":"25334","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15937","DOI":"10.1111\/jdv.15937"},{"key":"25335","doi-asserted-by":"crossref","unstructured":"Ho Lee Y, Gyu Song G. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis. J Clin Pharm Ther 2020; 45: 674-681.","DOI":"10.1111\/jcpt.13142"},{"key":"25336","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jcpt.13142","DOI":"10.1111\/jcpt.13142"},{"key":"25337","doi-asserted-by":"crossref","unstructured":"Guidelli GM, Viapiana O, Luciano N, De Santis M, Boffini N, Quartuccio L, et al. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study. Clin Exp Rheumatol 2021; 39: 868-873.","DOI":"10.55563\/clinexprheumatol\/pudtpo"},{"key":"25338","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.55563\/clinexprheumatol\/pudtpo","DOI":"10.55563\/clinexprheumatol\/pudtpo"},{"key":"25339","doi-asserted-by":"crossref","unstructured":"Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis 2016; 75: 831-841.","DOI":"10.1136\/annrheumdis-2014-205847"},{"key":"25340","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/annrheumdis-2014-205847","DOI":"10.1136\/annrheumdis-2014-205847"},{"key":"25341","doi-asserted-by":"crossref","unstructured":"Genovese MC, Kremer JM, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib, an oral Janus Kinase (JAK)1\/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to TNF inhibitors: results of the phase 3 RA-beacon study. Ann Rheum Dis 2015; 74: 753-776.","DOI":"10.1136\/annrheumdis-2015-eular.1427"},{"key":"25342","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/annrheumdis-2015-eular.1427","DOI":"10.1136\/annrheumdis-2015-eular.1427"},{"key":"25343","doi-asserted-by":"crossref","unstructured":"Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75: 1133-1138.","DOI":"10.1136\/annrheumdis-2015-207319"},{"key":"25344","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/annrheumdis-2015-207319","DOI":"10.1136\/annrheumdis-2015-207319"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/4536\/11949","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/4536\/11949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T15:09:47Z","timestamp":1674659387000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/4536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":120,"URL":"https:\/\/doi.org\/10.2340\/actadv.v103.4536","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,25]]}}}